Abstract
Triple-negative breast cancer (TNBC) the deadliest form of this disease currently lacks a targeted therapy and is characterized by increased risk of metastasis and presence of therapeutically resistant cancer stem cells (CSC). Recent evidence has demonstrated that the presence of an interferon (IFN)/signal transducer of activated transcription 1 (STAT1) gene signature correlates with improved therapeutic response and overall survival in TNBC patients. In agreement with these clinical observations, our recent work has demonstrated, in a cell model of TNBC that CSC have intrinsically repressed IFN signaling. Administration of IFN-β represses CSC properties, inducing a less aggressive non-CSC state. Moreover, an elevated IFN-β gene signature correlated with repressed CSC-related genes and an increased presence of tumor-infiltrating lymphocytes in TNBC specimens. We therefore propose that IFN-β be considered as a potential therapeutic option in the treatment of TNBC, to repress the CSC properties responsible for therapy failure. Future studies aim to improve methods to target delivery of IFN-β to tumors, to maximize therapeutic efficacy while minimizing systemic side effects.
References
Nov 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ralph R WeichselbaumAndy J Minn
Feb 13, 2009·Nature·Marieke A G EssersAndreas Trumpp
Jan 7, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Xiaoyang LingMichael Andreeff
Jul 24, 2012·Nature Medicine·Bradley N BidwellBelinda S Parker
Mar 14, 2013·Oncoimmunology·Clare Y SlaneyBelinda S Parker
Sep 26, 2013·The EMBO Journal·HyeonJoo CheonGeorge R Stark
Jan 9, 2014·Nature Communications·Geneviève GarcinGilles Uzé
Sep 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew D BursteinPowel H Brown
Oct 27, 2014·Nature Medicine·Antonella SistiguLaurence Zitvogel
Mar 3, 2015·Trends in Immunology·Rebecca A Porritt, Paul J Hertzog
Feb 26, 2016·Nature Reviews. Cancer·Belinda S ParkerPaul J Hertzog
Apr 16, 2016·Drug Discovery Today·Sophie SteelandClaude Libert
Jan 14, 2017·International Journal of Environmental Research and Public Health·Lin-Yu YuXiao-Ping Chen
Aug 30, 2017·Cancer Immunology Research·Natasha K BrockwellBelinda S Parker
Nov 23, 2017·Frontiers in Immunology·Yaozhong HuSerge Muyldermans
Dec 13, 2017·Proceedings of the National Academy of Sciences of the United States of America·Mary R DohertyMark W Jackson
Citations
Jan 29, 2019·PloS One·Yangjin KimSean Lawler
Aug 6, 2020·Frontiers in Cell and Developmental Biology·Wook Jin
May 10, 2019·Journal of Cellular Physiology·Jun WangCecilia Williams
Dec 11, 2019·Cancers·Eleonora AricòFilippo Belardelli
Jan 13, 2021·Cancers·Sandra Gessani, Filippo Belardelli
Apr 19, 2020·Biochimie·Dieuwertje E KokSergey A Krupenko
Aug 6, 2021·Journal of Molecular Graphics & Modelling·Oktay K GasymovJamil A Aliyev